- Company’s nonprovisional patent application includes claims to compositions, methods to support certain elements of preclinical and research programs
- Two international patent applications will grant Cybin the right to file future national applications into treaty member jurisdictions
- Cybin portfolio consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies and 4 active drug programs
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is moving forward to progress and strengthen its IP portfolio by filing three patents this month. After receiving an international search report of its May 2021 Patent Cooperation Treaty (“PCT”) application, Cybin filed a U.S. nonprovisional patent application claiming priority to the May 2021 PCT application (https://ibn.fm/MHCO7), and the company also filed two additional international patent applications, bringing the potential to obtain patent coverage in 153 countries (https://ibn.fm/mZ0BL).
According to the company, the International Patent Searching (“IPC”) authority provided a written opinion in support of the novelty, inventive steps and industrial applicability to multiple claims within Cybin’s patent filing. As a result, the nonprovisional patent application includes claims to compositions and methods to support certain elements of the company’s preclinical and research programs.
“Cybin’s portfolio now consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies, and 4 active drug programs targeting major depressive disorder, alcohol use disorder, anxiety and therapy-resistant psychiatric disorders,” said Cybin CEO Doug Drysdale. “We continue to progress our IP portfolio across novel molecules, delivery mechanisms, processes and protocols as we continue to find new and novel discoveries through our preclinical findings, thus expanding and strengthening IP.”
The two international patent applications, governed by the PCT, will grant Cybin the right to file future national applications into treaty member jurisdictions, including important potential markets for the company. In addition, the PCTs cover a library of phenethylamine and derivative drug-development candidates and methods of use.
One of Cybin’s PCT patent applications is in connection with a group of proprietary compounds identified by the company’s research data as being key for further evaluation toward selection as potential therapeutics. The other PCT application includes claims and disclosures toward several other proprietary novel psychedelic compounds, including compounds with positive research data, meeting the company’s internal research metrics. Cybin believes these applications will further strengthen its proprietary CYB005 program, which is targeting therapy-resistant psychiatric disorders, and will provide compositions for further evaluation in future research programs.
Cybin is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
